Ronald E. Blaylock, a director at Pfizer Inc. (NYSE:PFE), purchased 19,457 shares of the company's common stock. The ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.

Animal health company Zoetis (NYSE:ZTS) will be reporting results tomorrow before market open. Here’s what to look for.

Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while ...

RBC Capital Markets reiterated their positive stance on Alnylam Pharmaceuticals (NASDAQ:ALNY), maintaining an Outperform rating and a price target of $300.00. According to InvestingPro data, analyst ...

H.C. Wainwright research firm maintained a positive outlook on ORIC Pharmaceuticals (NASDAQ:ORIC), reiterating a Buy rating and a $21.00 price target for the company's stock. Currently trading at $11.

JMP Securities reiterated a Market Outperform rating on Enanta Pharmaceuticals (NASDAQ:ENTA) shares with a consistent price target of $21.00. The firm's analysis highlighted the company's solid ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to InvestingPro data ...

Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical industry. At recent prices, you can buy shares of Merck (NYSE: MRK) that ...